D

프리시젼바이오

335810KOSDAQ의료용 기기 제조업

39.0 / 100

Reference Date: 2026-06-10

Financial Score13.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 22.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

PrecisionBio is a specialized IVD company that develops diagnostic solutions using time-resolved fluorescence and gold absorption technologies for critical conditions such as cardiovascular and infectious diseases. Its key products include the Exdia TRF analyzer and cartridges, as well as clinical chemistry diagnostic products like Exdia PT10/PT10S. The company expanded into clinical chemistry diagnostics in 2021 and is developing a digital healthcare platform to integrate its diagnostic tools with digital services.

Number of Employees

97people

Average Salary

54.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 21.514.0Point
PBR
1.13Industry Average 1.384.0Point

In line with industry avg

ROE
-34.29Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
8.31Industry Average 11.655.0Point

Lower than industry avg (good)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼1.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼5.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,689Won52-week high 3,52052-week low 1,689
1-month return0.0Point

1m -22.88% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-05-15
  • Neutral분기보고서 (2026.03)2026-05-14